chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Before the vaccine my blood pressure was always below 130/80 often much lower. after the vaccine it went to around 160/100. it has stayed high.  Went to Ramipril 5mg then and currently, 06/14/2022, 10mg and blood pressure is still around 150/90. I do not have a history of high blood pressure.
Tender to the touch, swollen and red area as large as a  typical coffee cup, very hot, itchy
Experienced painful sensitivity in right front thigh which persisted until 11/20/09 when rash started to appear.  Treatment with Valtrex started 11/25/09 after phone consult with doctor. Follow-up received on 12/01/2009:  I did a terrible job of reporting my adverse reaction to an H1N1 vaccine (injection) that I received and subsequently was diagnosed with shingles, for which I have been treated.  Should I reenter the information in another report, the dates and times were okay but I assumed I was reporting adverse reaction to H1N1 vaccine injection, and I failed to report the pain and rash are "shingles".
INCORRECT PFIZER COVID 19 VACCINE ADMINISTERED - SHOULD have been pfizer covid 19 bivalent vaccine
exhausted/ tired; Fever; Chills/she had off and on chills; headache; This is a spontaneous report from a non-contactable nurse. A 29-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, from 11Jan2021 10:00 at a single dose, for covid-19 immunization. The patient has no other relevant medical history (reported as none). There were no concomitant medications used. The patient received her first dose of BNT162B2 on an unspecified date for covid-19 immunization. It was reported that she had an immune response to her 2nd COVID-19 vaccine received on 11Jan2021. She has had a fever, chills and headache during the night (11Jan2021). During the day on 12Jan2021, she had off and on chills and was exhausted. Today, (13Jan2020) patient reported she was feeling better, but still tired. Patient did not received treatment due to events. outcome of events fever, chills and headache was recovering. Outcome of event exhausted/tired was not recovered.   No follow-up attempts are possible. Information about lot/batch number cannot be obtained.
On  the morning of Jan 19, 2022, I experienced heart palpitations that continued throughout the day.  The palpitations stopped that evening, but they've been returning sporadically since that day. I have never before had a heart issue.  I visted  Dr. on Jan 31 2022.  My tests (EKG) were good, but I was referred to a cardiologist.  I will see that doctor on July 20, 2022.
The day afte receiving my third (booster) dose of the Pfizer vaccince, I suffered a stroke.
pain in the waist; must lie down; back pain; neck pain; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of NECK PAIN (neck pain), BACK PAIN (back pain), PAIN (pain in the waist) and FEELING OF RELAXATION (must lie down) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 27-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 05-Apr-2021, the patient experienced NECK PAIN (neck pain). On 06-Apr-2021, the patient experienced BACK PAIN (back pain). On 07-Apr-2021, the patient experienced PAIN (pain in the waist) and FEELING OF RELAXATION (must lie down). On 06-Apr-2021, NECK PAIN (neck pain) had resolved. On 07-Apr-2021, BACK PAIN (back pain) had resolved. At the time of the report, PAIN (pain in the waist) and FEELING OF RELAXATION (must lie down) outcome was unknown. Not Provided          Treatment include Tylenol. Concomitant product include cholesterol medication, high blood pressure medication.
stiff neck, localized occipital pain on the right side, pulsing at occipital sight, range of movement limited, been told it feels like shingles without the rash symptoms ongoing
Initial report received from a health care professional on 02 February 2011. An unidentified patient (age and sex not reported) received a bicep subcutaneous injection of ADACEL, manufacturer and lot number not provided. The patient received on an unknown date the vaccine shot below the deltoid in the bicep area and experienced an increased inflammatory response. The outcome was reported as unknown. Follow-up information was received from a health care professional on 17 May 2011. The patient was a 39 year-old female with no reported past medical history had received ADACEL, lot number U3491AA (sanofi pasteur Ltd. lot number C3637). Concomitant medication was reported as AUGMENTIN. No further information was available at the time of the report. The patient's outcome was reported as recovered. Documents held by sender: None.
Asthma; Osteoporosis; She hurt a bone on her spine; She checked her face for swelling and noted it was bright red like a sunburn; She checked her face for swelling and noted it was bright red like a sunburn; Inside her nose it felt funny, and in the outside of her eyes it felt funny; Her tongue felt a little roughed up; Felt woozy; Trouble seeing a little bit; This is a spontaneous report from a Contactable Consumer (patient).   A 58-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Batch/Lot Number: EP6955), via an unspecified route of administration on 24Mar2021 as single dose for COVID-19 immunization. Patient had no relevant medical history. The patient's concomitant medications were not reported. The patient got the first dose of the Pfizer Covid 19 vaccine yesterday and experienced asthma, osteoporosis, hurt a bone on her spine and takes prolia shots. The patient received the first dose and waited 15 minutes and they told her she could leave. While the patient was driving, inside her nose it felt funny and in the outside of her eyes it felt funny, the patient checked her face for swelling and noted it was bright red like a sunburn. The patient took Benadryl and her tongue felt a little roughed up and the patient did not had trouble breathing but felt woozy, had trouble seeing a little bit but stated it might had been complicated by the Benadryl since the patient never takes that medication. The patient get the second dose if the patient takes a Benadryl before the shot. The outcome of the event was unknown.  No follow-up attempts are possible. No further information is expected.
dizziness; my head is like bouncing; fatigue,tired and unable to work; fatigue,tired and unable to work; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A female patient received bnt162b2 (COMIRNATY), administration date 22Sep2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DIZZINESS (non-serious) with onset Sep2021, outcome "not recovered", described as "dizziness"; HEAD DISCOMFORT (non-serious) with onset Sep2021, outcome "not recovered", described as "my head is like bouncing"; FATIGUE (non-serious), LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (non-serious) all with onset Sep2021, outcome "not recovered" and all described as "fatigue,tired and unable to work".  Additional information: Caller received her 1st dose of the Pfizer BT Covid Vaccine last wednesday,22Sep2021, and she is still having side effects like dizziness ,"my head is like bouncing", fatigue, tired and unable to work. What should I take to treat my symptoms. The patient don't have any insurance to go to a doctor.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
at time vax pt exp pain at inject site. the day p/vax pt exp swelling in lymph nodes under arm where injected. has cough lasted about 3wks
Headache chills, body aches Narrative: pt had covid 12/25/2020
hallucinatory trip; fatigue; It was really weird because I've never had anything like that happen to me before; I felt paranoid; This is a spontaneous report from a contactable consumer. A 74-year-old male patient received the second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, batch/lot and expiration date unknown), via an unspecified route of administration on 04Mar2021 as a single dose for covid-19 immunization. The patient's medical history included visual impairment (reported as visually impaired) from an unknown date and unknown if ongoing. The patient's concomitant medications were not reported. The patient received the first dose of bnt162b2 on an unknown date for Covid-19 immunisation. On 05Mar2021, unusual side effect . He had a hallucinatory trip, He was seeing people in his room and got very concerned because he live alone. He was seeing movement in his room and felt paranoid. It was really weird because He never had anything like that happen to him before. He has not spoken with his primary care provider yet but he plans to call her next. The outcome of the events was unknown.  Information about the Lot/Batch number has been requested.
Suspected vaccination failure; diagnosed with shingles; first Shingrix dose on March 8, 2018 and the second dose on December 1, 2018; This case was reported by a consumer via call center representative and described the occurrence of suspected vaccination failure in a 72-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On 1st December 2018, the patient received the 2nd dose of Shingrix (intramuscular) .5 ml. On 8th March 2018, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. On 1st December 2018, unknown after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced drug dose administration interval too long. On 27th July 2021, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. The patient was treated with valaciclovir hydrochloride (Valacyclovir). On an unknown date, the outcome of the vaccination failure and drug dose administration interval too long were unknown and the outcome of the shingles was not recovered/not resolved.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix and Shingrix.  Additional details were reported as follows: The case was reported by the patient. At the time of reporitng, the age of the patient was 75 years. The patient received 2nd dose of Shingrix later than the recommended schedule, which led to lengthening of the vaccine schedule. On 27th July 2021, 969 days after receiving the 2nd dose and 1237 days after receiving the 1st dose, the patient was diagnosed with shingles. The patient was prescribed with Valacyclovir and that cause vomiting and went to the emergency room for the vomiting, refer case US2021AMR177242. This case was considered as suspected vaccination failure as details regarding laboratory test confirming shingles were unknown at the time of reporting. The reporter consented to follow up.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR177242:same reproter, same patient, different product (valacyclovir)
Pt presented for 2nd dose of Pfizer Covid vaccine on 4/5.  for second Pfizer COVID vaccine, and reported to have Left facial droop, and slurred speech same night after first dose.  He reports as soon as he made it home he  "felt sleepy and went to bed, and woke up around 8:00 pm with my tongue swollen and Left facial droop, and unable to speak." States he did not follow up with PCP or ER.Uon assessment by LVN and MD facial droop swollen tongue still present  2nd  COVID vaccine not give and instructed on EC visit. Pt diagnosed with CVA in EC. Pfizer noted as an allergy.
New physician goal to encourage adult immunization with the relatively new product Adacel was adopted by our organization's physicians and the vaccine was stocked in their office locations. Seven adult patient's received Daptacel (diphtheria, tetanus toxoids and acellular pertussis vaccine) instead of the intended Adacel (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) in one of our owned physician practice offices. There are no known adverse outcomes at this time. Patients have been sent letters regarding the need to avoid diphtheria testing before 10 years from the date of this immunization. The error was discovered by a nurse practitioner who routinely holds pediatric immunization clinic. The similarity of names and markings, while different in color, on the boxes contributed to this error. The new adoption of this product, coupled with the unwanted stock of Daptacel remaining in the pharmacy were also contributing factors.
Nausea and vomiting on Day 1 post vaccination.  Slight headache.  On Day 2, patient had fever.  No other family members were ill.  The patient baby sits for two children who were ill with N/V last week.
Patient fainted after vaccine administration. After lying down for 20 minutes, patient felt back to normal.
Reported Left arm numb and difficulty moving arm and fingers.  Writer examined student and he was able to move arm and fingers.  School nurse spoke with student and he was able to move arm and fingers without difficulty.  Alert and oriented x3. Respirations even and unlabored. Skin pink warm and dry.  No signs or symptoms of distress.  Student monitored longer then back to class without further difficulties.   Time of actual on set unknown, writer spoke with student around 11:30
swelling, redness, raised lump under the injection site. very hot to the touch and painful x 2 days
Patient had symptom onset on 11/6/2022 with cough and body aches. He tested positive for COVID-19 on 11/6/2022 at store with a NAA test. He had a known exposure to a positive COVID-19 case. Patient?s oncologist ordered outpatient monoclonal antibody infusion to treat the COVID. After IV insertion on 11/7/2022 in the outpatient department, patient had syncope and collapse and therefore he never received the monoclonal antibody infusion. He was admitted directly to the hospital for principal problem of syncope and collapse. and secondarily for COVID-19. Chest x-ray on 11/7/2022 showed findings suggestive of the beginnings of COVID-pneumonia with subtle ground glass opacity in the lateral mid and lower right lung. Vital signs normal but patient was initially hypoxic and put on oxygen. He improved and was no longer hypoxic, so oxygen removed. Patient denied shortness of breath or chest pain. He developed nausea, vomiting, diarrhea overnight on admission which was likely due to COVID. Patient continued to receive hospital care from 11/8/2022-11/10/2022 including IV fluids, vitamin C and zinc; no steroids needed. Monoclonal antibody treatment was considered as outpatient after discharge on 11/10/2022, as patient was eligible through 11/11/2022. Unknown if patient received MAB treatment.  On 11/22/2022, the patient presented at the emergency room with persistent cough and fevers. He was tested for COVID-19 and had positive COVID-19 antigen and PCR test results on 11/22/2022. He initially had tested positive on 11/6/2022. Patient complained of weakness, congestion, diarrhea, had a coarse deep sounding cough, and was dehydrated ? IV fluids given. Chest x-ray on 11/22/2022 showed no evidence of pneumonia; significantly low lung volumes; No definite focal airspace disease; mild central vascular congestion. Patient was admitted to the hospital on 11/22/2022 with principal problem of COVID-19 Virus Infection and secondary problem of Urinary Tract Infection associated with indwelling catheter. Further treatment and discharge information unknown.   On 11/30/2022, patient presented to the emergency room with 24-hour history of shortness of breath, cough, fever, fatigue and diarrhea. He had respiratory distress and hypoxia requiring oxygen. He was tested on 12/1/2022 for COVID-19 and had a positive NAA test. He initially tested COVID-19 positive on 11/6/2022, tested positive again on 11/22/2022, and on 12/1/2022. Patient was admitted to the hospital on 11/30/2022. Treatment included oxygen, steroids, nebulizers, broad spectrum antibiotics, and spot doses of diuretic. His condition worsened and on 12/4/2022 he requested to be transitioned to comfort measures. Patient expired on 12/5/2022. Death abstract states:  Acute Respiratory Failure, Pneumonia, and COVID-19 as causes of death.  Submitter does not have access to further medical information on this case. If more information is needed, please contact the admitting hospital:
Patient reported having a rash on hand and having difficulty breathing within 15 minutes of vaccination.  No treatment needed and patient was released to home.
tested positive with Covid-19, physician suggested Paxlovid. She asked where she can get the medication. she was fully immunized, boosted with Pfizer Covid19 Vaccine; she tested positive with Covid-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient.  A female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 3 (booster), single, (Batch/Lot number: unknown) as dose 2, single and (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), outcome "unknown", described as "tested positive with Covid-19, physician suggested Paxlovid. She asked where she can get the medication. she was fully immunized, boosted with Pfizer Covid19 Vaccine"; COVID-19 (medically significant), outcome "unknown", described as "she tested positive with Covid-19". The patient underwent the following laboratory tests and procedures: sars-cov-2 test positive: positive.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Systemic: Dizziness / Lightheadness-Mild, Systemic: Seizure-Mild, Systemic: Shakiness-Mild
PCR: Covid-19 Positive and related symptoms; PCR: Covid-19 Positive and related symptoms; This is a spontaneous report from a contactable consumer. This consumer reported for a 40-Year-old male (patient) that, A 40-years-old male patient received unknown dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Lot Number: not reported) via an unspecified route of administration on Apr2021 (at the age of 40-years-old) as dose number unknown, single for COVID-19 immunization. The patient medical history and concomitant medications were not reported. On Aug2021 the patient experienced PCR: COVID-19 positive and related symptoms (drug ineffective) (medically significant). PCR: COVID-19 positive and related symptoms (COVID-19) (medically significant). Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On Aug2021 the patient underwent lab tests and procedures which included sars-cov-2 test as positive (Nasal Swab). No other medications the patient received within 2 weeks of vaccination. Prior to vaccination, patient was not diagnosed with COVID-19. Since the vaccination, patient been tested for COVID-19. No prolonged hospitalization. Therapeutic measures were taken as a result of adverse events. Treatment received for the adverse event was Advil. The outcome of the events was unknown.  Follow-up(12Aug2021): This is a follow up spontaneous report in response to mail trail sent regarding the confirmation of below mentioned query. The response included that: Awareness date: 11Aug2021, EA: 11Aug2021 and Full vaccinated Best.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Initial report was received on 10 September 2012 from a health care professional. A 35 year-old female patient with a diabetic, hypothyroid and allergy to codeine - rash history had received on 28 August 2012 (also reported as 28/08/2012) an intramuscular right deltoid injection of FLUZONE, lot number UH719AD. On 03 September 2012 (also reported as 03/09/2012), the patient developed a 104 fever and a rash on torso, hands, face and lips. The patient was evaluated by her primary care physician on 07 September 2012 (also reported as 07/09/2012) and was treated with Prednisone for three days. No further information was available at the time of the report. The patient's outcome was unknown. Documents held by sender: None.
This spontaneous report as received from an Office Manager refers to unknown number of patients of unknown age. It was reported that since approximately 05-SEP-2012, doses of improperly stored GARDASIL might have been administered to patients (doses, route and lot numbers not reported). The vaccine was exposed to 24F for more than two excursions since 05-SEP-2012, the exact period of time that the vaccines were exposed to 24F is uncertain at this time, but the number of excursions totaled more than 2. This is one of several reports received from the same source (MARRS # 1210USA013248, 1210USA013249, 1210USA013250). Additional information has been requested.
Pt. received first dose of Moderna without incident. Received second dose on 6/8 and experienced extensive weakness. Son describes significant decline in cognitive function over the next ten days, as pt. became increasingly altered. She also switched from using a mix of language to communicate to only being able to use one. Pt. also became incontinent of stool and urine during this period. Pt. proceeded to have significant fall on 6/10. She was ultimately BIBA to the ED on 6/19 with concerns for altered mental status and failure to thrive. She was found to have a significant saccular aneurysm  of the descending thoracic aorta. Ultimate outcome of aneurysm is still pending, as this is a life-threatening disorder.
Case number PHEH2013US008350 is an initial spontaneous report received from a nurse on 10 Apr 2013. This report refers to a 16-years-old female patient. Her medical history and concomitant medications were not reported. She was vaccinated with MENVEO (batch number: M102006, expiry date: Oct 2014) at a dose of 0.5 ml intramuscularly on 04 Mar 2013. It was reported that the vaccine was at 33 F to 36 F for 19 days and it was not frozen. No further information was provided.
infection in my stomach that caused me to get diarrhea for 6 months; infection in my stomach that caused me to get diarrhea for 6 months; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP), Program ID: (201792).  A female patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary Immunization series complete; unknown manufacturer, Lot number and expiration date not provided.), for COVID-19 immunization. The following information was reported: GASTRIC INFECTION (non-serious), DIARRHOEA (non-serious), outcome "unknown" and all described as "infection in my stomach that caused me to get diarrhea for 6 months". The event "infection in my stomach that caused me to get diarrhea for 6 months" required physician office visit. Therapeutic measures were taken as a result of gastric infection, diarrhoea.  Additional Information: It was reported that the patient did not have a very good feeling about Pfizer because she had the vaccine for the coronavirus booster and ended up getting an infection in her stomach that caused her to get diarrhea for 6 months before the doctor found it (as reported) and gave her medication to treat the symptoms and infection.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.